Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9841996 | 0.84 | SIGMAR1 (0.38) | SIGMAR1CHRNB2CHRNA4AAK1ALOX5 | |
| SCHEMBL1157101 | 0.72 | — | — | |
| SCHEMBL147460 | 0.72 | — | — | |
| SCHEMBL8276437 | 0.71 | — | — | |
| SCHEMBL29438238 | 0.70 | ABCG2 (0.52) | ABCG2 | |
| SCHEMBL121646 | 0.70 | ABCG2 (0.52) | ABCG2 | |
| SCHEMBL2486004 | 0.68 | SIGMAR1 (0.52) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL16298139 | 0.67 | SIGMAR1 (0.50) | SIGMAR1CHRNB2CHRNA4AAK1 | |
| SCHEMBL2655460 | 0.67 | — | — | |
| SCHEMBL15674732 | 0.67 | OXTR (0.55) | SIGMAR1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3066690-A | — | — | None | — | — | JP | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20220151989-A1 | LIPOIC ACID PRODRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| WO-2020213693-A1 | LIPOIC ACID PRODRUG | 参天製薬株式会社 | 2020-10-22 | — | — | WO | disclosed |
| JP-H0366690-A | MANUFACTURE OF ASYMMETRIC SYNTHESIS OF FURO(3,4-C)PYRIDINE DERIVATIVE | SOC CONSEILS RECH APPL SCIENT SA (SCRAS) | 1991-03-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151989-A1 | LIPOIC ACID PRODRUG | ALOX15B, ALOX5, ALOX12 | SIGMAR1 4000/4885CHRNB2 3038/4885CHRNA4 3539/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | SIGMAR1 271/4885CHRNB2 2696/4885CHRNA4 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.